Related Experiment Videos
Defibrotide therapy for thrombophlebitis--controlled clinical trial
Insights
Defibrotide effectively treats acute thrombophlebitis by improving venous function and promoting fibrinolysis. This novel drug offers a safe alternative to traditional anticoagulants, showing no significant side effects in patients.
Area of Science:
- Vascular Medicine
- Pharmacology
Background:
- Deep venous thrombosis (DVT) presents significant acute and chronic complication risks.
- Current therapies like anticoagulants and fibrinolytic agents often cause severe side effects.
- Defibrotide offers a novel approach with antithrombotic and profibrinolytic properties, lacking anticoagulant activity and major adverse effects.
Purpose of the Study:
- To evaluate the efficacy of defibrotide in treating acute thrombophlebitis.
- To assess defibrotide's impact on fibrinolysis and venous function.
- To determine the safety profile of defibrotide in this patient group.
Main Methods:
- A group of 10 patients with acute thrombophlebitis received intravenous defibrotide (200 mg TID) for 15 days.
- Fibrinolysis parameters were monitored bi-daily.
- Venous function was assessed weekly using strain-gauge plethysmography and venous occlusion tests.
Main Results:
- Defibrotide treatment led to significant improvements in plethysmographic indices of venous function.
- A significant increase in profibrinolytic activity was observed.
- Patients experienced rapid resolution of clinical and instrumental signs of thrombophlebitis.
Conclusions:
- Defibrotide demonstrates significant efficacy in treating acute thrombophlebitis.
- The drug promotes profibrinolytic activity and enhances venous function.
- Defibrotide appears to be a safe treatment option for acute thrombophlebitis, with no reported side effects.
Abstract:
Deep venous thrombosis is a common disease with significant danger of both acute and chronic complications. Widely accepted therapies are based on anticoagulant (heparin and/or anticoagulant agents) or early fibrinolytic therapy. All these therapies frequently have severe side effects. Defibrotide is a new drug with antithrombotic and profibrinolytic activities but without anticoagulant activity and major side effects. To evaluate the efficacy of this drug against acute thrombophlebitis, we treated a group of 10 patients with 200 mg defibrotide intravenously three times a day for 15 days. Fibrinolysis parameters were monitored every other day. The indices of venous function by strain-gauge plethysmography and venous occlusion were evaluated every 7 days. The drug induced a significant improvement in plethysmographic indices and a significant profibrinolytic activity. Defibrotide-treated patients showed a fast disappearance of clinical and instrumental signs of thrombophlebitis. No side effects were reported during the study.